Baltaleucel-T

N/A

Report date: 2026/03/13 20:02:36

Base Information

Drug NameBaltaleucel-T
Drug Alias NameEBV-specific T-cells - CAGT/Cell MedicaEpstein Barr virus-specific T-cells - CAGT/Cell MedicaEBV-specific cytotoxic T-lymphocytes - CAGT/Cell MedicaEpstein Barr virus antigen-activated T-cells - CAGT/Cell MedicaEpstein Barr virus-specific cytotoxic T-lymphocytes - CAGT/Cell Medica +[8] 
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionEpstein-Barr nuclear antigen 1 modulators
TargetsEpstein-Barr nuclear antigen 1
Therapy Area/IndicationsLymphoproliferative DisordersNeoplasms, Plasma CellNasopharyngeal Carcinoma +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomFrance +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine
Inactive CompaniesCell Medica Ltd
Active IndicationsLymphoproliferative DisordersLymphoma, Non-HodgkinHodgkin Disease +[4] 
Inactive IndicationsNeoplasms, Plasma CellNasopharyngeal CarcinomaLeiomyosarcoma +[7] 

Other Information

ATC CodeN/A
Related LinksKEGG